Unichem APIs `Meloxicam' and `Zolpidem Tartrate' get European approval
19 Feb 2010
Unichem Laboratories has received regulatory approval in Europe for its two active pharma ingredients (APIs), Meloxicam and Zolpidem Tartrate, the company said in a filing with the Bombay Stock Exchange (BSE).
The European Directorate for the Quality of Medicines and Healthcare (EDQM), granted the company the Certificate of suitability European Pharmacopeia (CEP) for the two drugs, Unichem said.
Early this month, the Medicines and Healthcare Products Regulatory Agencies, UK had re-certified Unichem Laboratories' Ghaziabad formulation facility.
Medicines manufactured in the facility are re-certified for both human as well as veterinary use, the company said in a release.
Unichem Laboratories reported a 19.8 per cent rise year-on-year increase in its net profit in the October-December 2009-10 quarter, at Rs33.68 crore. The company's net sales increased 14.9 per cent to Rs171.36 crore in the December 2009 quarter.
Unichem Laboratories is engaged in the manufacture and marketing of pharmaceutical formulations, bulk drugs and drug intermediates.
Its domestic formulation business grew 18.6 per cent and API business grew at 26.3 per cent, compared with the corresponding quarter of the previous year.
The Unichem pharma division has over 25 brands for pain management, anti infectives, anti allergics, digestives and nutritionals like Trinergic and Aroff.
